QTX125
CAS No. 1279698-31-5
QTX125( QTX 125 | QTX-125 )
Catalog No. M11154 CAS No. 1279698-31-5
QTX125 (QTX-125) is a novel potent, selective HDAC6 inhibitor, displays excellent selectivity over other HDACs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 873 | Get Quote |
|
50MG | 1782 | Get Quote |
|
100MG | 2250 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameQTX125
-
NoteResearch use only, not for human use.
-
Brief DescriptionQTX125 (QTX-125) is a novel potent, selective HDAC6 inhibitor, displays excellent selectivity over other HDACs.
-
DescriptionQTX125 (QTX-125) is a novel potent, selective HDAC6 inhibitor, displays excellent selectivity over other HDACs; strongly reduces cell viability with IC50 values of 0.120 and 0.182 uM in two primary samples obtained from patients with MCL; causes cell-growth inhibition and programmed cell death in association with increased levels of acetylated α-tubulin, also antitumoral effect is particularly evident in MCL models, both in culture and in vivo, surpassing the efficacy of currently available HDAC6 inhibitors.
-
In VitroQTX125 (25-500 nM; 24-48 hours) treatment induces the subsequent apoptosis demonstrated by annexin V/propidium iodide double staining and the cleavage of caspase-9, caspase-8, caspase-3, and PARP. In MCL cell lines MINO, REC-1, IRM-2 and HBL-2 cells, QTX125 (10 nM, 10 μM, 100 μM) induces dose-dependent hyperacetylation of α-tubulin.QTX125 has the strongest growth-inhibitory effect in Burkitt cell lymphoma, follicular lymphoma, and mantle cell lymphoma (MCL). Apoptosis Analysis Cell Line:MINO, REC-1, IRM-2 and HBL-2 cells Concentration:25 nM, 50 nM, 100 nM, 500 nM Incubation Time:24 hours, 48 hours Result:Inhibited annexin V/propidium iodide double staining.Western Blot Analysis Cell Line:MINO, REC-1, IRM-2 and HBL-2 cells Concentration:25 nM, 50 nM, 100 nM, 500 nM Incubation Time:24 hours Result:Inhibited the cleavage of caspase-9, caspase-8, caspase-3, and PARP.
-
In VivoQTX125 (60 mg/kg; i.p.; daily dosing for 5 days; for 4 weeks) treatment inhibits tumor growth in REC-1 or MINO cells xenografted in nude mice. Animal Model:Nude mice bearing REC-1 or MINO cells Dosage:60 mg/kg Administration:Intraperitoneal administration; daily dosing for 5 days; for 4 weeks Result:Inhibited tumor growth in REC-1 or MINO cells xenografted in nude mice.
-
SynonymsQTX 125 | QTX-125
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1279698-31-5
-
Formula Weight417.421
-
Molecular FormulaC23H19N3O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(C1=C(C2=COC=C2)C=C(C3=CC=C(O)C=C3)N1)NCC4=CC=C(C(NO)=O)C=C4
-
Chemical Name3-(3-furyl)-N-{4-[(hydroxyamino)carbonyl]benzyl}-5-(4-hydroxyphenyl)-1H-pyrrole2-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Perez-Salvia M, et al. Haematologica. 2018 Jun 7. pii: haematol.2018.189241.
molnova catalog
related products
-
SBHA
SBHA (suberohydroxamic acid) is a Histone deacetylase (HDAC) inhibitor. HDAC is required for transcriptional modulation, cell cycle regulation and development.
-
HDAC6 inhibitor NCT-...
A potent, selective HDAC6 inhibitor with IC50 of 84 nM, with IC50s of >3.5 uM for the other HDAC isoforms.
-
Pandacostat
Pandacostat is the first nonselective HDAC inhibitor (pan-HDACi).